{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:27:29Z","timestamp":1790836049349,"version":"4.1.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004710","name":"Fondazione Umberto Veronesi","doi-asserted-by":"publisher","award":["Research fellowship"],"award-info":[{"award-number":["Research fellowship"]}],"id":[{"id":"10.13039\/501100004710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["M2\/2"],"award-info":[{"award-number":["M2\/2"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["RC4.1, 2018-2020"],"award-info":[{"award-number":["RC4.1, 2018-2020"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunotherapy with checkpoint inhibitors (CPIs) strongly improved the outcome of metastatic melanoma patients. However, not all the patients respond to treatment and identification of prognostic biomarkers able to select responding patients is currently of outmost importance. Considering that development of vitiligo-like depigmentation in melanoma patients represents both an adverse event of CPIs and a favorable prognostic factor, we analyzed soluble biomarkers of vitiligo to validate them as early indicators of response to CPIs. Fifty-seven metastatic melanoma patients receiving CPIs were enrolled and divided according to the best overall response to treatment. Patient sera were evaluated at pre-treatment and after 1 and 3\u00a0months of therapy. We found that basal CD25 serum levels were higher in stable and responding patients and remained higher during the first 3\u00a0months of CPI therapy compared to non-responders. CXCL9 was absent in non-responding patients before therapy beginning. Moreover, an increase of CXCL9 levels was observed at 1 and 3\u00a0months of therapy for all patients, although higher CXCL9 amounts were present in stable and responding compared to non-responding patients. Variations in circulating immune cell subsets was also analyzed, revealing a reduced number of regulatory T lymphocytes in responding patients. Altogether, our data indicate that a pre-existing and maintained activation of the immune system could be an indication of response to CPI treatment in melanoma patients.<\/jats:p>","DOI":"10.1038\/s41598-022-09373-9","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T06:04:10Z","timestamp":1648706650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients"],"prefix":"10.1038","volume":"12","author":[{"given":"Maria Luigia","family":"Carbone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Bove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Mastroeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauretta","family":"Levati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaelena","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Antonio","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"De Galitiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"D\u2019Atri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Fortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Maria","family":"Failla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"9373_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer. 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer."},{"key":"9373_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.clim.2016.07.006","volume":"172","author":"B Herzberg","year":"2016","unstructured":"Herzberg, B. & Fisher, D. E. Metastatic melanoma and immunotherapy HHS public access. Clin. Immunol. 172, 105\u2013110 (2016).","journal-title":"Clin. Immunol."},{"key":"9373_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"9373_CR4","first-page":"267","volume":"3","author":"I M\u00e1rquez-Rodas","year":"2015","unstructured":"M\u00e1rquez-Rodas, I. et al. Immune checkpoint inhibitors: Therapeutic advances in melanoma. Ann. Transl. Med. 3, 267 (2015).","journal-title":"Ann. Transl. Med."},{"key":"9373_CR5","first-page":"296","volume":"179","author":"MT Wan","year":"2018","unstructured":"Wan, M. T. & Ming, M. E. Nivolumab versus ipilimumab in the treatment of advanced melanoma: A critical appraisal. Br. J. Dermatol. 179, 296\u2013300 (2018).","journal-title":"Br. J. Dermatol."},{"key":"9373_CR6","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","volume":"9","author":"K Buder-Bakhaya","year":"2018","unstructured":"Buder-Bakhaya, K. & Hassel, J. C. Biomarkers for clinical benefit of immune checkpoint inhibitor treatment\u2014A review from the melanoma perspective and beyond. Front. Immunol. 9, 1474 (2018).","journal-title":"Front. Immunol."},{"key":"9373_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0864-3","volume":"17","author":"M Yi","year":"2018","unstructured":"Yi, M. et al. Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors. Mol. Cancer. 17, 1\u201314 (2018).","journal-title":"Mol. Cancer."},{"key":"9373_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-020-01749-x","volume":"39","author":"XH Jia","year":"2020","unstructured":"Jia, X. H. et al. The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors. J. Exp. Clin. Cancer Res. 39, 1\u201317 (2020).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"9373_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore, J. et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1\/PD-L1 clinical trials. Pigment Cell Melanoma Res. 28, 245\u2013253 (2015).","journal-title":"Pigment Cell Melanoma Res."},{"key":"9373_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11912-016-0509-x","volume":"18","author":"MA Postow","year":"2016","unstructured":"Postow, M. A., Friedman, C. F. & Postow, M. A. Emerging tissue and blood-based biomarkers that may predict response to immune checkpoint inhibition. Curr. Oncol. Rep. 18, 21 (2016).","journal-title":"Curr. Oncol. Rep."},{"key":"9373_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2020.02105","volume":"11","author":"F Maibach","year":"2020","unstructured":"Maibach, F., Sadozai, H., Seyed Jafari, S. M., Hunger, R. E. & Schenk, M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front. Immunol. 11, 1\u201320 (2020).","journal-title":"Front. Immunol."},{"key":"9373_CR12","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1158\/1535-7163.MCT-17-0386","volume":"16","author":"AM Goodman","year":"2017","unstructured":"Goodman, A. M. et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16, 2598\u20132608 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"9373_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0383-1","volume":"6","author":"M Capone","year":"2018","unstructured":"Capone, M. et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J. Immunother. Cancer. 6, 1\u20137 (2018).","journal-title":"J. Immunother. Cancer."},{"key":"9373_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/cncr.32506","volume":"126","author":"EK Bartlett","year":"2020","unstructured":"Bartlett, E. K. et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. Cancer 126, 76\u201385 (2020).","journal-title":"Cancer"},{"key":"9373_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CMR.0000000000000520","volume":"29","author":"F Petrelli","year":"2019","unstructured":"Petrelli, F. et al. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: A systematic review and meta-analysis. Melanoma Res. 29, 1\u201312 (2019).","journal-title":"Melanoma Res."},{"key":"9373_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/bjc.2015.467","volume":"114","author":"S Diem","year":"2016","unstructured":"Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer. 114, 256\u2013261 (2016).","journal-title":"Br. J. Cancer."},{"key":"9373_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000842","volume":"8","author":"AS Laino","year":"2020","unstructured":"Laino, A. S. et al. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J. Immunother. Cancer. 8, e000842 (2020).","journal-title":"J. Immunother. Cancer."},{"key":"9373_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001689","volume":"8","author":"R Turiello","year":"2020","unstructured":"Turiello, R. et al. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy. J. Immunother. Cancer. 8, e001689 (2020).","journal-title":"J. Immunother. Cancer."},{"key":"9373_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02285-0","volume":"18","author":"M Capone","year":"2020","unstructured":"Capone, M. et al. Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients. J. Transl. Med. 18, 1\u201310 (2020).","journal-title":"J. Transl. Med."},{"key":"9373_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s10147-019-01588-7","volume":"25","author":"K Chamoto","year":"2020","unstructured":"Chamoto, K., Hatae, R. & Honjo, T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int. J. Clin. Oncol. 25, 790\u2013800 (2020).","journal-title":"Int. J. Clin. Oncol."},{"key":"9373_CR21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","volume":"31","author":"J Haanen","year":"2020","unstructured":"Haanen, J. et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy. Ann. Oncol. 31, 724\u2013744 (2020).","journal-title":"Ann. Oncol."},{"key":"9373_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jaad.2020.04.058","volume":"83","author":"AB Simonsen","year":"2020","unstructured":"Simonsen, A. B., Kaae, J., Ellebaek, E., Svane, I. M. & Zachariae, C. Cutaneous adverse reactions to anti-PD-1 treatment\u2014A systematic review. J. Am. Acad. Dermatol. 83, 1415\u20131424 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"9373_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues, M., Ezzedine, K., Hamzavi, I., Pandya, A. G. & Harris, J. E. New discoveries in the pathogenesis and classification of vitiligo. J. Am. Acad. Dermatol. 77, 1\u201313 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"9373_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/0974-2077.112667","volume":"6","author":"D Parsad","year":"2013","unstructured":"Parsad, D. & Sahni, K. Stability in vitiligo: Is there a perfect way to predict it?. J. Cutan. Aesthet. Surg. 6, 75 (2013).","journal-title":"J. Cutan. Aesthet. Surg."},{"key":"9373_CR25","doi-asserted-by":"publisher","first-page":"684","DOI":"10.18632\/oncotarget.323","volume":"2","author":"KT Byrne","year":"2011","unstructured":"Byrne, K. T. & Turk, M. J. New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget 2, 684\u2013694 (2011).","journal-title":"Oncotarget"},{"key":"9373_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings, H. E. et al. Vitiligo-like depigmentation in patients with stage III\u2013IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. J. Clin. Oncol. 33, 773\u2013781 (2015).","journal-title":"J. Clin. Oncol."},{"key":"9373_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","volume":"152","author":"C Hua","year":"2016","unstructured":"Hua, C. et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 152, 45\u201351 (2016).","journal-title":"JAMA Dermatol."},{"key":"9373_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/1346-8138.13520","volume":"44","author":"Y Nakamura","year":"2017","unstructured":"Nakamura, Y. et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study. J. Dermatol. 44, 117\u2013122 (2017).","journal-title":"J. Dermatol."},{"key":"9373_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40264-019-00875-6","volume":"43","author":"S Babai","year":"2020","unstructured":"Babai, S., Voisin, A. L., Bertin, C., Gouverneur, A. & Le-Louet, H. Occurrences and outcomes of immune checkpoint inhibitors-induced vitiligo in cancer patients: A retrospective cohort study. Drug Saf. 43, 111\u2013117 (2020).","journal-title":"Drug Saf."},{"key":"9373_CR30","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.3390\/ijms20225731","volume":"20","author":"CM Failla","year":"2019","unstructured":"Failla, C. M., Carbone, M. L., Fortes, C., Pagnanelli, G. & D\u2019atri, S. Melanoma and vitiligo: In good company. Int. J. Mol. Sci. 20, 5731 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"9373_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.autrev.2017.07.005","volume":"16","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert, R., Speeckaert, M., De Schepper, S. & van Geel, N. Biomarkers of disease activity in vitiligo: A systematic review. Autoimmun. Rev. 16, 937\u2013945 (2017).","journal-title":"Autoimmun. Rev."},{"key":"9373_CR32","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.14416","volume":"174","author":"XX Wang","year":"2016","unstructured":"Wang, X. X. et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br. J. Dermatol. 174, 1318\u20131326 (2016).","journal-title":"Br. J. Dermatol."},{"key":"9373_CR33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/pcmr.12559","volume":"30","author":"A Maouia","year":"2017","unstructured":"Maouia, A. et al. Differential expression of CXCL9, CXCL10, and IFN-\u03b3 in vitiligo and alopecia areata patients. Pigment Cell Melanoma Res. 30, 259\u2013261 (2017).","journal-title":"Pigment Cell Melanoma Res."},{"key":"9373_CR34","first-page":"E303","volume":"169","author":"G Elia","year":"2018","unstructured":"Elia, G. MIG Th1 chemokine in Vitiligo. Clin Ther. 169, E303\u2013E307 (2018).","journal-title":"Clin Ther."},{"key":"9373_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/pcmr.12667","volume":"31","author":"M Abdallah","year":"2018","unstructured":"Abdallah, M. et al. CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study. Pigment Cell Melanoma Res. 31, 330\u2013336 (2018).","journal-title":"Pigment Cell Melanoma Res."},{"key":"9373_CR36","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","volume":"6","author":"M Rashighi","year":"2014","unstructured":"Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 6, 223ra23 (2014).","journal-title":"Sci. Transl. Med."},{"key":"9373_CR37","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jid.2017.01.033","volume":"137","author":"R Speeckaert","year":"2017","unstructured":"Speeckaert, R., Voet, S., Hoste, E. & van Geel, N. S100B is a potential disease activity marker in nonsegmental vitiligo. J. Investig. Dermatol. 137, 1445\u20131453 (2017).","journal-title":"J. Investig. Dermatol."},{"key":"9373_CR38","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.jid.2017.03.021","volume":"137","author":"SA Birlea","year":"2017","unstructured":"Birlea, S. A. S100B: Correlation with active vitiligo depigmentation. J. Investig. Dermatol. 137, 1408\u20131410 (2017).","journal-title":"J. Investig. Dermatol."},{"key":"9373_CR39","first-page":"208","volume":"61","author":"P Acharya","year":"2020","unstructured":"Acharya, P. & Mathur, M. Interleukin-17 level in patients with vitiligo: A systematic review and meta-analysis. Australas J. Dermatol. 61, 208\u2013212 (2020).","journal-title":"Australas J. Dermatol."},{"key":"9373_CR40","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.autrev.2016.01.004","volume":"15","author":"RK Singh","year":"2016","unstructured":"Singh, R. K. et al. The role of IL-17 in vitiligo: A review. Autoimmun. Rev. 15, 397\u2013404 (2016).","journal-title":"Autoimmun. Rev."},{"key":"9373_CR41","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1346-8138.1997.tb02292.x","volume":"24","author":"Y Honda","year":"1997","unstructured":"Honda, Y., Okubo, Y. & Koga, M. Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo. J. Dermatol. 24, 561\u2013563 (1997).","journal-title":"J. Dermatol."},{"key":"9373_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0923-1811(98)00070-X","volume":"19","author":"UC Yeo","year":"1999","unstructured":"Yeo, U. C. et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J. Dermatol. Sci. 19, 182\u2013188 (1999).","journal-title":"J. Dermatol. Sci."},{"key":"9373_CR43","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/jamadermatol.2016.2366","volume":"152","author":"R Speeckaert","year":"2016","unstructured":"Speeckaert, R., Lambert, J. & Van Geel, N. Clinical significance of serum soluble CD molecules to assess disease activity in vitiligo. JAMA Dermatol. 152, 1194\u20131200 (2016).","journal-title":"JAMA Dermatol."},{"key":"9373_CR44","first-page":"3","volume":"11","author":"MI ElGhareeb","year":"2019","unstructured":"ElGhareeb, M. I., El Mokadem, S., El Sayed, B. & Khalifa, N. Soluble CD27 and MIF as possible serum biomarkers of vitiligo activity in Egyptian patients in Sharkia Governorate. Dermatol. Rep. 11, 3\u20135 (2019).","journal-title":"Dermatol. Rep."},{"key":"9373_CR45","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1007\/s11033-020-05336-3","volume":"47","author":"S Yan","year":"2020","unstructured":"Yan, S., Shi, J., Sun, D. & Lyu, L. Current insight into the roles of microRNA in vitiligo. Mol. Biol. Rep. 47, 3211\u20133219 (2020).","journal-title":"Mol. Biol. Rep."},{"key":"9373_CR46","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/pcmr.12086","volume":"26","author":"YL Shi","year":"2013","unstructured":"Shi, Y. L. et al. MicroRNA expression profiling identifies potential serum biomarkers for non-segmental vitiligo. Pigment Cell Melanoma Res. 26, 418\u2013421 (2013).","journal-title":"Pigment Cell Melanoma Res."},{"key":"9373_CR47","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/cdd.2015.117","volume":"23","author":"Q Shi","year":"2016","unstructured":"Shi, Q. et al. Oxidative stress-induced overexpression of miR-25: The mechanism underlying the degeneration of melanocytes in vitiligo. Cell Death Differ. 23, 496\u2013508 (2016).","journal-title":"Cell Death Differ."},{"key":"9373_CR48","doi-asserted-by":"crossref","unstructured":"Verkhovskaia, S. et al. Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients. J. Cancer Res. Clin. Oncol.  (2021).","DOI":"10.21203\/rs.3.rs-827134\/v1"},{"key":"9373_CR49","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek, T. R. & Castro, I. Interleukin-2 receptor signaling: At the interface between tolerance and immunity. Immunity 33, 153\u2013165 (2010).","journal-title":"Immunity"},{"key":"9373_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang, T., Zhou, C. & Ren, S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 5, e1163462 (2016).","journal-title":"Oncoimmunology."},{"key":"9373_CR51","doi-asserted-by":"publisher","first-page":"108515","DOI":"10.1016\/j.clim.2020.108515","volume":"218","author":"J Damoiseaux","year":"2020","unstructured":"Damoiseaux, J. The IL-2\u2013IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor. Clin. Immunol. 218, 108515 (2020).","journal-title":"Clin. Immunol."},{"key":"9373_CR52","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins, M. B. et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17, 2105\u20132116 (1999).","journal-title":"J. Clin. Oncol."},{"key":"9373_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01570-9","volume":"8","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Regulatory T cells control toxicity in a humanized model of IL-2 therapy. Nat. Commun. 8, 1\u201312 (2017).","journal-title":"Nat. Commun."},{"key":"9373_CR54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"9373_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007980","volume":"4","author":"TM Brusko","year":"2009","unstructured":"Brusko, T. M. et al. Influence of membrane CD25 stability on T lymphocyte activity: Implications for immunoregulation. PLoS\u00a0One. 4, e7980 (2009).","journal-title":"PLoS\u00a0One."},{"key":"9373_CR56","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","volume":"29","author":"K Kohli","year":"2021","unstructured":"Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29, 10\u201321 (2021).","journal-title":"Cancer Gene Ther."},{"key":"9373_CR57","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","volume":"317","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 in T cell function. Exp. Cell Res. 317, 620\u2013631 (2011).","journal-title":"Exp. Cell Res."},{"key":"9373_CR58","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.immuni.2012.11.012","volume":"38","author":"W Kastenm\u00fcller","year":"2013","unstructured":"Kastenm\u00fcller, W. et al. Peripheral prepositioning and local CXCL9 chemokine-mediated guidance orchestrate rapid memory CD8+ T cell responses in the lymph node. Immunity 38, 502\u2013513 (2013).","journal-title":"Immunity"},{"key":"9373_CR59","doi-asserted-by":"crossref","unstructured":"Kuo, P. T., Zeng, Z., Salim, N., Mattarollo, S., Wells, J. W., Leggatt, G. R. The role of CXCR3 and its chemokine ligands in skin disease and cancer. Front. Med. (2018).","DOI":"10.3389\/fmed.2018.00271"},{"key":"9373_CR60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fmed.2018.00351","volume":"5","author":"JA Bridge","year":"2018","unstructured":"Bridge, J. A., Lee, J. C., Daud, A., Wells, J. W. & Bluestone, J. A. Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front. Med. 5, 351 (2018).","journal-title":"Front. Med."},{"key":"9373_CR61","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/cas.13226","volume":"108","author":"N Yamazaki","year":"2017","unstructured":"Yamazaki, N. et al. Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. Cancer Sci. 108, 1022\u20131031 (2017).","journal-title":"Cancer Sci."},{"key":"9373_CR62","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/j.immuni.2019.04.010","volume":"50","author":"MT Chow","year":"2019","unstructured":"Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50, 1498\u20131512 (2019).","journal-title":"Immunity"},{"key":"9373_CR63","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj, D. et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell 35, 885-900.e10 (2019).","journal-title":"Cancer Cell"},{"key":"9373_CR64","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1158\/0008-5472.CAN-15-2303","volume":"75","author":"Y Koguchi","year":"2015","unstructured":"Koguchi, Y. et al. Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab. Cancer Res. 75, 5084\u20135092 (2015).","journal-title":"Cancer Res."},{"key":"9373_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga, R. et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation\u2014A target for novel cancer therapy. Cancer Treat. Rev. 63, 40\u201347 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"9373_CR66","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1084\/jem.20052144","volume":"203","author":"JM Burns","year":"2006","unstructured":"Burns, J. M. et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201\u20132213 (2006).","journal-title":"J. Exp. Med."},{"key":"9373_CR67","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1111\/cas.14069","volume":"110","author":"Y Ohue","year":"2019","unstructured":"Ohue, Y. & Nishikawa, H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. Cancer Sci 110, 2080\u20132089 (2019).","journal-title":"Cancer Sci"},{"key":"9373_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188439","volume":"1874","author":"T Li","year":"2020","unstructured":"Li, T., Wu, B., Yang, T., Zhang, L. & Jin, K. The outstanding antitumor capacity of CD4 + T helper lymphocytes. Biochim. Biophys. Acta Rev. Cancer. 1874, 188439 (2020).","journal-title":"Biochim. Biophys. Acta Rev. Cancer."},{"key":"9373_CR69","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce, C. M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10, 704\u2013714 (2009).","journal-title":"Nat. Rev. Genet."},{"key":"9373_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-015-0113-7","volume":"22","author":"SH Chan","year":"2015","unstructured":"Chan, S. H. & Wang, L. H. Regulation of cancer metastasis by microRNAs. J. Biomed. Sci. 22, 1\u201312 (2015).","journal-title":"J. Biomed. Sci."},{"key":"9373_CR71","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3390\/cancers11030326","volume":"11","author":"AG Michniewicz","year":"2019","unstructured":"Michniewicz, A. G. & Czyz, M. Role of mirnas in melanoma metastasis. Cancers (Basel). 11, 326 (2019).","journal-title":"Cancers (Basel)."},{"key":"9373_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21124544","volume":"21","author":"ML Motti","year":"2020","unstructured":"Motti, M. L., Minopoli, M., Di Carluccio, G., Ascierto, P. A. & Carriero, M. V. Micrornas as key players in melanoma cell resistance to mapk and immune checkpoint inhibitors. Int. J. Mol. Sci. 21, 1\u201316 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"9373_CR73","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3390\/ijms21030878","volume":"21","author":"F Varrone","year":"2020","unstructured":"Varrone, F. & Caputo, E. The miRNAs role in melanoma and in its resistance to therapy. Int. J. Mol. Sci. 21, 878 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"9373_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2020.00071","volume":"8","author":"M Neagu","year":"2020","unstructured":"Neagu, M., Constantin, C., Cretoiu, S. M. & Zurac, S. miRNAs in the diagnosis and prognosis of skin cancer. Front. Cell Dev. Biol. 8, 1\u201317 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"9373_CR75","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejca.2015.10.009","volume":"53","author":"H Mirzaei","year":"2016","unstructured":"Mirzaei, H. et al. MicroRNAs as potential diagnostic and prognostic biomarkers in melanoma. Eur. J. Cancer. 53, 25\u201332 (2016).","journal-title":"Eur. J. Cancer."},{"key":"9373_CR76","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/cells9020415","volume":"9","author":"C Lorusso","year":"2020","unstructured":"Lorusso, C., De Summa, S., Pinto, R., Danza, K. & Tommasi, S. miRNAs as key players in the management of cutaneous melanoma. Cells 9, 415 (2020).","journal-title":"Cells"},{"key":"9373_CR77","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jid.2015.12.041","volume":"136","author":"S Guo","year":"2016","unstructured":"Guo, S. et al. Serum miR-16: A potential biomarker for predicting melanoma prognosis. J. Investig. Dermatol. 136, 985\u2013993 (2016).","journal-title":"J. Investig. Dermatol."},{"key":"9373_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep08201","volume":"5","author":"T Ohira","year":"2015","unstructured":"Ohira, T. et al. MiR-19b regulates hTERT mRNA expression through targeting PITX1 mRNA in melanoma cells. Sci. Rep. 5, 1\u20139 (2015).","journal-title":"Sci. Rep."},{"key":"9373_CR79","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/ijms17111124","volume":"17","author":"J Huo","year":"2016","unstructured":"Huo, J. et al. Upregulated microRNA-25 mediates the migration of melanoma cells by targeting DKK3 through the WNT\/\u03b2-catenin pathway. Int. J. Mol. Sci. 17, 1124 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"9373_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1051\/medsci\/201834f111","volume":"34","author":"Q-Q Jiang","year":"2018","unstructured":"Jiang, Q.-Q. & Liu, W.-B. miR-25 promotes melanoma progression by regulating RNA binding motif protein 47. M\u00e9decine\/Sciences. 34, 59\u201365 (2018).","journal-title":"M\u00e9decine\/Sciences."},{"key":"9373_CR81","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","volume":"25","author":"JE Gershenwald","year":"2018","unstructured":"Gershenwald, J. E. & Scolyer, R. A. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann. Surg. Oncol. 25, 2105\u20132110 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"9373_CR82","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour, L. et al. iRECIST: Guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 18, e143\u2013e152 (2017).","journal-title":"Lancet Oncol."},{"key":"9373_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40644-019-0281-x","volume":"20","author":"T Persigehl","year":"2020","unstructured":"Persigehl, T., Lennartz, S. & Schwartz, L. H. IRECIST: How to do it. Cancer Imaging 20, 1\u20137 (2020).","journal-title":"Cancer Imaging"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09373-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09373-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T20:28:48Z","timestamp":1669321728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-09373-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["9373"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-09373-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-753314\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"13 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Paolo A. Ascierto has\/had a consultant\/advisory role for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Array, Merck Serono, Pierre-Fabre, Incyte, Medimmune, AstraZeneca, Syndax, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandoz, Im-munocore, 4SC, Alk-ermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore. He also received research funding from Bristol Myers Squibb, Roche-Genentech, Array, Sanofi, and travel support from MSD. All outside the submitted work. All the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5448"}}